文献速递眼底病与葡萄膜炎

RIDE与RISE试验中糖尿病视网膜病变的全视网膜光凝:并非「一劳永逸」

Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".
PubMed 文献 · Ophthalmology · 2019-08-21

该研究对RIDE和RISE两项3期临床试验进行事后分析,评估糖尿病视网膜病变(DR)和糖尿病黄斑水肿(DME)患者全视网膜光凝(PRP)的治疗与再治疗模式。基线无PRP者中,假手术组9.5%至第24个月接受至少1次PRP,雷珠单抗0.3 mg组和0.5 mg组分别为1.1%和1.6%(P<0.001);基线有PRP者中,假手术组19.3%接受PRP,雷珠单抗组无患者需额外PRP(P<0.001)。结论认为PRP并非「一劳永逸」,雷珠单抗可减少PRP治疗和DR进展。

要点

  • 基线无PRP患者至第24个月需PRP的比例:假手术组9.5% vs 雷珠单抗0.3 mg组1.1%和0.5 mg组1.6%(P<0.001)。
  • 基线有PRP患者至第24个月需额外PRP的比例:假手术组19.3% vs 雷珠单抗组0%(P<0.001)。
  • 基线有PRP患者至第24个月发生新增殖事件概率:假手术组39.4% vs 雷珠单抗0.3 mg组10.3%和0.5 mg组9.9%(P<0.0001)。

核心结论

  • 在RIDE和RISE中,PRP并非「一劳永逸」的操作,基线有或无PRP的患者在研究期间均出现PRP再治疗。
  • 无论基线PRP状态如何,雷珠单抗治疗均减少了研究期间的PRP治疗和DR进展。

研究设计与样本

  • RIDE(NCT00473382)和RISE(NCT00473330)3期临床试验的的事后分析,评估雷珠单抗治疗DME。
  • 共759例患者随机接受治疗。

主要发现

  • 基线时约25%的患者曾接受PRP:假手术组22.2%、雷珠单抗0.3 mg组24.4%、雷珠单抗0.5 mg组25.4%。
  • 基线无PRP患者(n=577)至第24个月接受至少1次PRP的比例:假手术组9.5% vs 雷珠单抗0.3 mg组1.1%和0.5 mg组1.6%(P<0.001)。
  • 基线有PRP患者(n=182)至第24个月接受至少1次PRP的比例:假手术组19.3% vs 雷珠单抗组0%(P<0.001)。
  • 基线有PRP患者至第24个月发生新增殖事件的概率:假手术组39.4% vs 雷珠单抗0.3 mg组10.3%和0.5 mg组9.9%(P<0.0001)。
  • 总体而言,假手术组患者(包括基线无PRP后需PRP者)经历的临床事件多于雷珠单抗组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate panretinal photocoagulation (PRP) treatment and re-treatment patterns in patients with diabetic retinopathy (DR) and diabetic macular edema (DME). DESIGN: Post hoc analysis of the phase 3 RIDE (clinicaltrials.gov identifier, NCT00473382) and RISE (clinicaltrials.gov identifier, NCT00473330) clinical trials of ranibizumab for the treatment of DME. PARTICIPANTS: Seven hundred fifty-nine patients were randomized for treatment. METHODS: Panretinal photocoagulation treatment patterns and clinical experiences were assessed by baseline PRP treatment status. MAIN OUTCOME MEASURES: Number and timing of on-study PRP treatment sessions undergone through month 24. Time to new proliferative event (composite end point) was also assessed. RESULTS: At baseline, approximately 25% of patients in RIDE and RISE had undergone PRP treatment before enrollment (22.2%, 24.4%, and 25.4% of patients in the sham, ranibizumab 0.3 mg, and ranibizumab 0.5 mg arms, respectively). In patients without prior PRP at baseline (n = 577), 9.5% of sham-treated patients underwent 1 or more PRP treatments through month 24, compared with 1.1% and 1.6% of patients receiving ranibizumab 0.3 mg and ranibizumab 0.5 mg, respectively (P < 0.001 for both ranibizumab arms vs. sham). In patients with prior PRP at baseline (n = 182), 19.3% of sham-treated patients underwent 1 or more PRP treatments through month 24. No ranibizumab-treated patients with prior PRP at baseline required additional on-study PRP through month 24 (P < 0.001 for both ranibizumab arms vs. sham). Ranibizumab treatment also significantly reduced clinical DR progression among patients who underwent prior PRP. By month 24 in patients with prior PRP at baseline, the probability of experiencing a new proliferative event was 10.3% and 9.9% in patients receiving ranibizumab 0.3 mg and ranibizumab 0.5 mg treatment, respectively, compared with 39.4% in sham-treated patients (P < 0.0001). Overall, sham-treated patients, including those patients who were PRP naïve at baseline who went on to require PRP, experienced more clinical events than ranibizumab-treated patients. CONCLUSIONS: In RIDE and RISE, PRP treatment was not a "1 and done" procedure, with on-study PRP re-treatment occurring in patients both with and without prior PRP treatment at baseline. Ranibizumab treatment reduced on-study PRP treatment and DR progression regardless of prior PRP treatment status at baseline.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Gonzalez VH, Wang PW, Ruiz CQ, et al. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done". Ophthalmology. 2019. PMID: 31668888. doi:10.1016/j.ophtha.2019.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。